ESPR
Esperion Therapeutics, Inc.
Esperion Therapeutics, Inc. (ESPR) is currently in an uptrend, trading above both the 50-day and 200-day moving averages. RSI is at 64.5, with 3/3 trend checks passing.
ESPR with MA50 and MA200
Key levels & signals
Esperion Therapeutics, Inc. (ESPR) is still trading in a constructive trend overall. The latest available price is $3.18, and 3 of 3 core trend checks are currently passing. Price is trading above the 50-day moving average by 1.9% and above the 200-day moving average by 4.0%.
ESPR currently has an RSI reading of 64.5, which leans mildly positive without looking too stretched. In other words, momentum is supportive, but not yet extreme enough to dominate the entire chart read.
For traders reviewing ESPR next, the key question is whether the trend still looks healthy or whether price has started to outrun itself. A strong uptrend can stay strong, but entries often become more difficult when price is already extended, so many traders will watch for pullbacks, support reactions, or fresh bases rather than chasing strength blindly.
About Esperion Therapeutics, Inc.
Esperion Therapeutics, Inc. operates as a pharmaceutical firm, concentrating on the development and commercialization of treatments for individuals with high levels of low-density lipoprotein (LDL) cholesterol. The company's flagship pharmaceutical products are NEXLETOL (bempedoic acid) and NEXLIZET (a tablet combining bempedoic acid and ezetimibe), prescribed for managing conditions such as atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. In addition, Esperion maintains a licensing and collaborative partnership with Daiichi Sankyo Europe GmbH, alongside an agreement with Serometrix to acquire rights to an oral, small molecule PCSK9 inhibitor program. Established in 2008, the company's corporate offices are situated in Ann Arbor, Michigan.
ESPR shares outstanding over time
Tracking total shares outstanding is one way to spot dilution — a rising line means the company has issued more shares (stock-based compensation, secondary offerings, convertible debt), which spreads the same earnings and ownership across more shares. A falling line usually reflects buybacks.
Learn the indicators behind this page
More stock opportunities
Common questions about ESPR
Is this page a buy or sell recommendation?
No. This page is designed to help you review chart structure, momentum and technical context more quickly, but it is not personal financial advice.
Why can a stock look bullish and overbought at the same time?
Strong trending stocks can still become stretched in the short term. That is why trend traders and dip buyers can read the same chart differently.
What should I do next after reading this page?
Open the full dashboard, review the chart in more detail, compare indicators, and decide whether the setup still makes sense within your own process.